Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 1

Status

Completed 4

Sponsor Class

INDUSTRY 3UNKNOWN 1

Study Type

Interventional 4

Sponsor

Conditions

Pain 6Cancer Pain 4Neoplasms 2

Interventions

Morphine 6nabiximols 4Oxycodone 3Fentanyl 3Methadone 2Hydromorphone 2Acetaminophen 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1resiniferatoxin 1naloxegol 1Tapentadol 1Sugars 1Standard of Care 1Lidocaine 1Inosine Monophosphate 1Donepezil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Cancer Pain × nabiximols × Clear all
NCT01337089 2023-04-12

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Jazz Pharmaceuticals

Phase 3 Completed
660 enrolled 9 charts

Cancer Pain, Pain

NCT01361607 2023-04-12

SPRAY III

Jazz Pharmaceuticals

Phase 3 Completed
399 enrolled 17 charts

Cancer Pain, Pain

NCT01424566 2023-04-12

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Jazz Pharmaceuticals

Phase 3 Completed
406 enrolled 16 charts

Cancer Pain, Pain

NCT01262651 2018-04-23

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

GWPharm

Phase 3 Completed
397 enrolled 18 charts

Cancer Pain, Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡